Tor Vergata University of Rome, also known as the University of Rome II, is a public research university located in Rome, Italy.

During the past decade, Università degli studi di Roma "Tor Vergata" conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Università degli studi di Roma "Tor Vergata"" #1 sponsor was "Janssen Research & Development, LLC" with 2 trials, followed by "University of Rome Tor Vergata" with 2 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "Edwards Lifesciences" with 1 trials sponsored and "Fondazione Italiana Linfomi ONLUS" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Università degli studi di Roma "Tor Vergata"" #1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator and "SPIGC" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Università degli studi di Roma "Tor Vergata"" are "Multiple Myeloma" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Anticoagulants" (1 trials), "COVID-19" (1 trials) and "COVID-19 Pandemic" (1 trials). Many other conditions were trialed in "Università degli studi di Roma "Tor Vergata"" in a lesser frequency.

Most popular intervention types in "Università degli studi di Roma "Tor Vergata"" are "Drug" (7 trials), "Device" (2 trials), "Behavioral" (1 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "ARA-C" (1 trials), "ASCT" (1 trials), "BCNU" (1 trials), "COVID-surg-SPIGC questionnaire" (1 trials) and "Carfilzomib 20 mg/m^2" (1 trials). Other intervention names were less common.

The vast majority of trials in "Università degli studi di Roma "Tor Vergata"" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Università degli studi di Roma "Tor Vergata"". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Università degli studi di Roma "Tor Vergata", undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Università degli studi di Roma "Tor Vergata", 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".